IP Library Granted Patent US 8,552,198
Granted Patent B2
US 8,552,198 · App. 13/591,992 · Granted Oct 8, 2013

Benzimidazole compound crystal

Inventors: Akira Fujishima (Hyogo, JP); Isao Aoki (Hyogo, JP); Keiji Kamiyama (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,552,198
App. No.
13/591,992
Granted
Oct 8, 2013
Kind
B2
Abstract

A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.

Claims (10)

1. A method for producing a crystal of a compound of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or salt thereof or a hydrate thereof, which comprises:

subjecting a racemate of the compound of 2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole to an optical resolution so as to obtain (R)-2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole as in an amorphous form;

dissolving the compound in the amorphous form in a solvent so as to obtain a solution of (R)-2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole dissolved in the solvent;

concentrating the solution or adding water to the solution so as to crystallize (R)-2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole; and

isolating a crystal of (R)-2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole from the solution or the solution to which the water is added,

wherein the solvent is at least one solvent selected from the group consisting of acetonitrile, acetone, and water, and

(i) if the solvent is acetonitrile, the solvent is gradually evaporated at room temperature for the crystallization of the compound, whereby the crystal of the compound is produced,

(ii) if the solvent is acetone, water is added to the solution for the crystallization of the compound, whereby the crystal of the compound is produced, and

(iii) if the solvent is ethanol, water is added to the solution for the crystallization of the compound, whereby the crystal of the hydrate of the compound is produced.

2. The method according to claim 1 , wherein the optical resolution is carried out by using a chiral column.

Priority Claims (1)
JP 11-171509 · Jun 17, 1999 · national
Continuity (9)
Division 13223988 · Sep 1, 2011
Continuation 12771486 · Apr 30, 2010
Continuation 12393409 · Feb 26, 2009
Continuation 12006845 · Jan 7, 2008
Continuation 11149903 · Jun 10, 2005
Continuation 10655114 · Sep 4, 2003
Continuation 10243329 · Sep 13, 2002
Continuation 09674624
Related Publication 20120316344A1 · Dec 13, 2012